Navigation Links
DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
Date:11/22/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 22, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco.  Enrollment in the first four cohorts of the VAL-083 trial has been completed with no significant adverse events or dose limiting toxicity (DLT) observed.  Twenty five percent of patients evaluated in Cohorts 1-3 exhibited stable disease or tumor-regression and improved disease symptoms.  Evaluation and clinical observations of Cohort 4 is ongoing. 

"The fact that we are seeing evidence of clinical activity against refractory GBM at this stage is very promising," said Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals. "VAL-083 is safe and well-tolerated by patients at the doses tested to date, and based on historical data, we anticipate seeing stronger patient benefit and tumor responses as we achieve higher doses."

DelMar's Phase 1/2 study is an open-label, single arm dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of VAL-083 in patients with recurrent GBM.  Patients in the trial must have been previously treated for GBM with surgery and/or radiation and must have failed both Avastin® and Temodar®, unless either or both are contra-indicated. 

Details of the presentation:- Maximum tolerated dose (MTD) has not yet been reached. 

- Enrollment of Cohort 5 (20mg/m2) is expected in December 2013, subject to complet
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
2. DelMar Pharmaceuticals Gives Quarterly Shareholder Update
3. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
4. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
5. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
6. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
7. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
8. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
9. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
10. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
11. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... VIEJO, Calif., Oct. 12, 2011 Avanir Pharmaceuticals, Inc. ... affect (PBA) prevalence data from stroke survivors will be ... Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine in ... details about the data presentation at ACRM/ASNR Progress ...
... Good Start Genetics,™ Inc., an innovative molecular diagnostics ... screening, today announced that it will present results ... next-generation DNA sequencing platform at the Annual Meeting ...  ASRM will be held from October 15-19, 2011 ...
Cached Medicine Technology:Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference 2Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM) 2
(Date:4/23/2014)... from healthy, unrelated donors was safe and effective ... by Clostridium difficile , according to a ... Diseases and available online. Known as fecal ... given via a colonoscope or a nasogastric tube. ... promising treatment more readily available to patients. , ...
(Date:4/23/2014)... John J. O,Shea, M.D., scientific director at the National ... has been named the 2014 recipient of the Ross ... peer-reviewed, open-access journal Molecular Medicine . The award ... York Academy of Sciences in Manhattan, followed by scientific ... is part of the National Institutes of Health. , ...
(Date:4/23/2014)... have developed a way to detect and measure cancer ... particles with tails of synthetic DNA., A team led ... used gold nanoparticles to target and bind to fragments ... variants, which can indicate the presence and stage of ... in a cell can be determined by examining the ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
(Date:4/23/2014)... As evidence mounts showing the potential health benefits of ... people are taking supplements. And the chemical industry is ... supplements, health effects could deter growth, so the industry ... claims, according to the cover story in Chemical ... of the American Chemical Society. , Melody M. Bomgardner, ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... Billion Industry and 12% Growth of Frozen Desserts Nationwide Fuels ... ... Feb. 12 Cefiore, Southern,California-based and one of the nation,s fastest-growing ... for,Valentine,s Day. With more than 90% of U.S. households consuming frozen,desserts ...
... Feb. 12 Peter Ochinko, President of Ft.,Lauderdale-based ... initiative,with top-rated risk assessment software developer RiskWatch, Inc. ... the former Corporate Director,of Security at Memorial Healthcare ... impressive that in 2006, Memorial won the,esteemed Lindberg ...
... Blue Buffalo Foundation for Cancer,Research, http://www.petcancerawareness.com, ... for canine and feline cancer,has made a ... in the,nonprofit,s global effort to cure canine ... Foundation has provided financial sponsorship for two,important ...
... Sheets: CGCP), announced that the company will release,results for ... 2007 prior,to market open on Tuesday, March 4, 2008. ... Senior Vice President and Chief Financial,Officer William R. Abbott ... p.m. Eastern time (9:00 a.m. Pacific time) to review ...
... What do smiling Buddhas,and serious dieters have ... to,fucoPROTEIN bars, they just might lose unwanted pounds. ... America fucoPROTEIN bar, a dietary,supplement that contains fucoxanthin. ... a marine thermogenic that burns fat and boosts,metabolism., ...
... Studies show that only 2 in 5 seek any ... and stress,being one of today,s most common disorders, it ... Mental Health America,organization, leaving more than 40 million people ... feelings of anxiety -- muscle tension,headache, nausea, fatigue, or ...
Cached Medicine News:Health News:Latest Salvo Fired in Frozen Yogurt Wars as Southern California's Fastest-Growing Franchise - Cefiore - Launches New Chocolate Flavor 2Health News:IAS Teams Up with RiskWatch to Offer New Hospital Security and School Security Risk Assessments 2Health News:The Blue Buffalo Foundation for Cancer Research Sponsors Six Morris Animal Foundation Cancer Studies 2Health News:Cardiogenesis Corporation to Report 2007 Fourth Quarter and Year-End Results on March 4th 2Health News:Burn Fat with fucoPROTEIN(TM) Bars 2Health News:40 Million Americans Endure Anxiety Everyday 2
Infusion Cannula, 2.0mm....
Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°....
Micro Vitreoretinal Cannula; Angled; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 65°, 1mm from Tip....
...
Medicine Products: